From the Editor

Apr 01, 2003
Pharmaceutical Executive
The trick in understanding any contentious public debate is to figure out what's being left out of the discussion. What, for example, is the assumption that's so obvious that no one thinks to bring it up? More often than not, when you've located that assumption, you've found the secret core of the argument -- the part that everyone's really fighting over and no one can bear to mention.
Mar 01, 2003
Pharmaceutical Executive
No greater challenge faces any writer than the empty page. To sully that beautiful white space with mere words can seem so arrogant, so pretentious, that one's urge is to leave it alone, in perfect blankness. To paraphrase an old writer's adage, just to begin may require lowering your standards-an act salvaged later only by careful editing.
Feb 01, 2003
Pharmaceutical Executive
We all feast from the same kettle-and this season, we're not just feasting; we're swimming in a war-fired stew of events and issues.
Jan 01, 2003
Pharmaceutical Executive
Don't try this at home. That ought to be the common lesson we draw from most examples of pharma's current performance in the public arena.
Dec 01, 2002
Pharmaceutical Executive
On the last stop of a recent trip, I checked into the Bethesda Marriott. It was late afternoon, and as I entered my room, I flicked on the TV set and switched to the cable news. "Five Shootings, Five Dead, in 17 Hours," read the streamer, while the large screen showed a map of the area west of DC.
Nov 01, 2002
Pharmaceutical Executive
PR is more than free ink. It is even more than good free ink.
Oct 01, 2002
Pharmaceutical Executive
I was wondering whether I could take any more pain, when the moment slowed to a crawl. Pain wakened fear. Eternity lingered alongside. Mortality, grinning over my shoulder, blew a chill breath across the nape of my neck. "Dying would end the pain," I thought. "But I don't want to die like this."
Sep 01, 2002
Pharmaceutical Executive
Sixteen years ago I began to edit Pharmaceutical Executive, a magazine unknown to me only a few months before. Today, I wonder how much I've learned in all the time since.
Aug 01, 2002
Pharmaceutical Executive
Just when pharma companies finally awake to the need for a good reputation, the stakes go vertical. The long-perceived and possibly illusory gap between shareholder behavior and public outrage suddenly disappears. And each company stands or falls on its revealed record.
Jul 01, 2002
Pharmaceutical Executive
This season, boosterism is out; hedging is in. Yet a realistic assessment of the pharma market, even under the shadow of terror and war, reveals new opportunities. For every ominous sign or setback, a potential line of offense exists. Despite the press of a slow economy, nervous investors, customer consolidation, and cost-shifting in healthcare, the industry remains rich in resources, growth, and opportunity. Here are some of the market forces, issues, and opportunities for the pharma universe this year:
native1_300x100
lorem ipsum